There’s hope for treating one of the deadliest forms of cancer.
A pancreatic cancer vaccine has proven to be effective in half of patients treated in a small trial, according to a study published in the journal Nature on Wednesday.
Pancreatic cancer — often called the “silent killer,” since symptoms don’t show up in most patients until it has spread to other organs — occurs when cells in the pancreas mutate and form a tumor.
Memorial Sloan Kettering Cancer Center in New York sent tumor samples from 16 patients to scientists at BioNTech in Germany, the same company Pfizer teamed up with to produce COVID-19 vaccines.
After scientists analyzed proteins in patient’s cancer cells, they used messenger RNA — a molecule that contains instructions to direct cells to make a protein — in a vaccine for each patient, attempting to tell the immune system to attack the cancer cells.
Costs, however, remain a barrier, since each vaccine must be customized, Dr. Neeha Zaidi, a pancreatic cancer specialist at Johns Hopkins University School of Medicine, told the publication.
About 64,050 people will be diagnosed with the deadly disease this year. Pancreatic cancer accounts for about 3% of all cancers in the US, and around 7% of all cancer deaths, according to the American Cancer Society.
https://nypost.com/2023/05/11/vaccine-for-silent-killer-pancreatic-cancer-shows-promise/
Comments
Post a Comment